Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

BACKGROUND: Dual inhibition of PD-1/PD-L1 and TGF-β pathways is a rational therapeutic strategy for malignancies. SHR-1701 is a new bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor II. This first-in-human trial aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dan, Zhou, Jun, Wang, Yongsheng, Li, Mingjun, Jiang, Haiping, Liu, Yunpeng, Yin, Xianli, Ge, Minghua, Xiang, Xiaojun, Ying, Jieer, Huang, Jian, Zhang, Yan-qiao, Cheng, Ying, Huang, Zhigang, Yuan, Xianglin, Han, Weiqing, Yan, Dong, Wang, Xinshuai, Liu, Pan, Wang, Linna, Zhang, Xiaojing, Luo, Suxia, Liu, Tianshu, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594927/
https://www.ncbi.nlm.nih.gov/pubmed/36280870
http://dx.doi.org/10.1186/s12916-022-02605-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594927/
https://www.ncbi.nlm.nih.gov/pubmed/36280870
http://dx.doi.org/10.1186/s12916-022-02605-9

Ejemplares similares